Pierrel
Italy 172 employees Updated 9 July 2026
Pierrel is a finished-dose manufacturer based in Italy. It appears in 49 regulatory filings across 14 regulators, without an active US DMF or CEP on file. Its filings concentrate with Health Canada, EMA and ANSM (FR). Its GMP standing is certified by EMA. Its most recent recorded inspection, by US FDA, closed on 23 March 2023 as VAI.
4
registered plants
1 with an FDA FEI number
49
filings
across 14 regulators
These figures were checked against the regulators' own files on 25 July 2026
Inspections
6 of 6 confirmed
Sources: FDA Establishment Registration, read 4 May 2026. FDA drug inspection classifications, read 4 May 2026. EudraGMDP (MIA + third-country GMP certs), read 4 May 2026.
Inspection history
- 23 March 2023 VAI US FDA
- 15 February 2019 VAI US FDA
- 26 June 2018 NAI US FDA
- 6 June 2014 VAI US FDA
- 5 March 2012 VAI US FDA
- 31 July 2009 VAI US FDA
NAI means no action indicated, VAI means voluntary action indicated, and OAI means
official action indicated.
Registered plants
| Site | FDA FEI |
| Capua(CE), United Arab Emirates | Not on file |
| CAPUA, Italy | Not on file |
| Italy, Italy | 3006999064 |
| CE, Italy | Not on file |
Filings and GMP by regulator
| Regulator | Filings | GMP certificates |
| Health Canada | 10 | None |
| EMA | 7 | 6 |
| ANSM (FR) | 6 | None |
| AIFA (IT) | 6 | None |
| SFDA (Saudi Arabia) | 4 | None |
| NCELS (KZ) | 3 | None |
Comparing suppliers?
Choose your molecules and target markets. Pierrel comes back tiered against every other
supplier able to file there.
Start for free No sales call.
Open risk flags
- The most recent inspection outcome was VAI, on 23 March 2023.
Sources on this page
- FDA
- Drug master files, establishment registration, inspection classifications
- EDQM
- Certificates of suitability
- EudraGMDP and national regulators
- GMP certificates